Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 8/20 | 0.69 |
| ▸ | PTH1R | Q03431 | 8/20 | 0.65 |
| ▸ | GLP1R | P43220 | 3/20 | 0.64 |
| ▸ | CCKBR | P32239 | 1/20 | 0.64 |
| ▸ | GRPR | P30550 | 1/20 | 0.62 |
| ▸ | GCGR | P47871 | 1/20 | 0.60 |
| ▸ | GIPR | P48546 | 1/20 | 0.60 |
| ▸ | ECE1 | P42892 | 1/20 | 0.60 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31182558 | 0.93 | RXFP1 (0.72) | RXFP1PTH1RGLP1RCCKBRGCGR | |
| SCHEMBL30658281 | 0.92 | PTH1R (0.64) | RXFP1PTH1RGLP1RCCKBRGCGR | |
| SCHEMBL30658325 | 0.92 | RXFP1 (0.69) | RXFP1PTH1RGLP1RCCKBRECE1 | |
| SCHEMBL30658299 | 0.91 | KEAP1 (0.69) | PTH1RGLP1RCCKBRGCGRECE1 | |
| SCHEMBL30862316 | 0.90 | RXFP1 (0.80) | RXFP1PTH1RGLP1RCCKBRGCGR | |
| SCHEMBL30658258 | 0.90 | PTH1R (0.69) | RXFP1PTH1RGLP1RCCKBRGCGR | |
| SCHEMBL17940396 | 0.89 | RXFP1 (0.72) | RXFP1PTH1RGLP1RCCKBRECE1 | |
| SCHEMBL31169784 | 0.89 | IL23R (0.69) | GLP1RCCKBRGCGRGIPR | |
| SCHEMBL30906408 | 0.89 | RXFP1 (0.69) | RXFP1PTH1RGLP1RCCKBRGRPR | |
| SCHEMBL31020886 | 0.88 | RXFP1 (0.66) | RXFP1PTH1RGLP1RCCKBRGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753627-B2 | Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-12 | — | — | US | disclosed |